SLC5A2 and acute myocardial infarction: Empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2), is well-established for managing various cardio-renal conditions, but its effectiveness in patients recovering from acute myocardial infarction (AMI) remains unclear.